Arcadia Biosciences Stock Price, News & Analysis (NASDAQ:RKDA) $2.88 -0.02 (-0.69%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$2.75▼$2.9550-Day Range$2.65▼$4.0652-Week Range$2.60▼$18.94Volume21,927 shsAverage Volume63,776 shsMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Arcadia Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside420.6% Upside$15.00 Price TargetShort InterestHealthy0.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.27) to ($3.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Arcadia Biosciences has a forecasted upside of 420.6% from its current price of $2.88.Amount of Analyst CoverageArcadia Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.80% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 52.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RKDA. Previous Next 2.5 News and Social Media Coverage News SentimentArcadia Biosciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RKDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 12.61% of the stock of Arcadia Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcadia Biosciences are expected to grow in the coming year, from ($7.27) to ($3.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcadia Biosciences Stock (NASDAQ:RKDA)Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.Read More RKDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RKDA Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Stock Crosses Below Fifty Day Moving Average of $3.24November 29, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)December 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 28, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Bunge, The Andersons and Arcadia BiosciencesNovember 11, 2023 | finance.yahoo.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | finance.yahoo.comQ3 2023 Arcadia Biosciences Inc Earnings CallNovember 9, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Strong Third Quarter 2023 Financial Results and Business HighlightsNovember 1, 2023 | bizjournals.comDavis biotechnology company Arcadia Biosciences appears to move headquarters to DallasDecember 1, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 26, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Date of Third Quarter 2023 Financial Results and Business Highlights Conference CallOctober 3, 2023 | finance.yahoo.comGoodWheat™ Introduces Clean Plate Guarantee, Celebrates Picky Eaters for National Pasta MonthAugust 12, 2023 | benzinga.comArcadia Biosciences Stock (NASDAQ:RKDA), Earnings Estimates, EPS, and RevenueAugust 11, 2023 | finance.yahoo.comQ2 2023 Arcadia Biosciences Inc Earnings CallAugust 11, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Reports Q2 Loss, Misses Revenue EstimatesAugust 10, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2023 Financial Results and Business HighlightsAugust 9, 2023 | finance.yahoo.comOrion (OEC) Misses Q2 Earnings and Revenue EstimatesJuly 28, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Date of Second Quarter 2023 Financial Results and Business Highlights Conference CallJuly 25, 2023 | msn.comHC Wainwright & Co. Reiterates Arcadia Biosciences (RKDA) Buy RecommendationJuly 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Arcadia Biosciences (RKDA)July 21, 2023 | bizjournals.comDavis-based Arcadia Biosciences engages investment bank Lake Street Capital to explore strategic optionsJuly 20, 2023 | marketwatch.comArcadia Biosciences Shares Rise 6.8% After Beginning Strategic ReviewJuly 20, 2023 | benzinga.comArcadia Biosciences Seeks Strategic Options; Warns On Challenging Economic HeadwindsJuly 20, 2023 | msn.comArcadia Biosciences stock jumps as company explores possible saleJuly 20, 2023 | uk.finance.yahoo.comRKDA - Arcadia Biosciences, Inc.July 20, 2023 | marketwatch.comArcadia Biosciences to Explore Potential Sale, Merger in Strategic ReviewJuly 20, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Strategic ReviewJuly 17, 2023 | finance.yahoo.comArcadia Biosciences (RKDA) Launches GoodWheat™ into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes™See More Headlines Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Agricultural production - crops Sub-IndustryN/A SectorBasic Materials Current SymbolNASDAQ:RKDA CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+420.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($18.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,380,000.00 Net Margins-279.74% Pretax Margin-290.32% Return on Equity-77.09% Return on Assets-49.74% Debt Debt-to-Equity RatioN/A Current Ratio5.15 Quick Ratio4.47 Sales & Book Value Annual Sales$9.96 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$13.87 per share Price / Book0.21Miscellaneous Outstanding Shares1,110,000Free Float1,088,000Market Cap$3.20 million OptionableNot Optionable Beta0.92 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Stanley E. Jacot Jr. (Age 53)President, CEO & Director Comp: $527.9kMs. Laura Pitlik (Age 49)Chief Marketing Officer Comp: $374kMr. Thomas J. Schaefer (Age 47)CFO & Corporate Secretary Mr. Brian SchafferSenior Vice President of SalesMr. Tracy BakerSenior Vice President of Seamless Technical OperationsKey CompetitorsIT Tech PackagingNYSE:ITPTantechNASDAQ:TANHGolden MineralsNYSE:AUMNAustin GoldNYSE:AUSTVenator MaterialsNYSE:VNTRQView All CompetitorsInsiders & InstitutionsSabby Management LLCSold 85,508 shares on 11/15/2023Ownership: 2.946%Thomas J SchaeferBought 649 shares on 8/4/2023Total: $2,381.83 ($3.67/share)Stanley Jacot JrBought 5,000 shares on 5/30/2023Total: $21,550.00 ($4.31/share)Thomas J SchaeferBought 700 shares on 2/1/2023Total: $161.00 ($0.23/share)View All Insider TransactionsView All Institutional Transactions RKDA Stock Analysis - Frequently Asked Questions Should I buy or sell Arcadia Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RKDA shares. View RKDA analyst ratings or view top-rated stocks. What is Arcadia Biosciences' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month price objectives for Arcadia Biosciences' shares. Their RKDA share price targets range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 420.6% from the stock's current price. View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts. How have RKDA shares performed in 2023? Arcadia Biosciences' stock was trading at $0.2710 at the start of the year. Since then, RKDA shares have increased by 963.1% and is now trading at $2.8811. View the best growth stocks for 2023 here. Are investors shorting Arcadia Biosciences? Arcadia Biosciences saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,800 shares, a decrease of 52.9% from the October 31st total of 10,200 shares. Based on an average trading volume of 16,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the shares of the company are sold short. View Arcadia Biosciences' Short Interest. When is Arcadia Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our RKDA earnings forecast. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its quarterly earnings results on Thursday, November, 9th. The basic materials company reported ($1.83) earnings per share for the quarter, beating analysts' consensus estimates of ($2.67) by $0.84. The basic materials company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.89 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 77.09% and a negative net margin of 279.74%. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO? 1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Arcadia Biosciences IPO? (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. Who are Arcadia Biosciences' major shareholders? Arcadia Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Sabby Management LLC (2.95%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer. View institutional ownership trends. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:RKDA) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.